Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From Asia With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Results From the Phase III Trial CLEOPATRA
| Autor: | David Miles, José Baselga, Adam Knott, Seock-Ah Im, Valorie F. Chan, Graham Ross, Young-Hyuck Im, Sandra M. Swain, Emma Clark |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Oncology Cancer Research medicine.medical_specialty Receptor ErbB-2 Population Breast Neoplasms Docetaxel Pharmacology Antibodies Monoclonal Humanized Biomarkers Pharmacological Double-Blind Method Trastuzumab Internal medicine Breast Cancer Antineoplastic Combined Chemotherapy Protocols Humans Medicine skin and connective tissue diseases education neoplasms Aged Aged 80 and over education.field_of_study business.industry Hazard ratio Middle Aged medicine.disease Metastatic breast cancer Regimen Treatment Outcome Female Taxoids Pertuzumab business Febrile neutropenia medicine.drug |
| Zdroj: | The Oncologist. 19:693-701 |
| ISSN: | 1549-490X 1083-7159 |
| DOI: | 10.1634/theoncologist.2014-0033 |
| Popis: | Introduction. We report detailed safety analyses by geographic region from the phase III study CLEOPATRA with pertuzumab, trastuzumab, and docetaxel in patients with human epidermal growth factor receptor 2 (HER2)-positive first-line metastatic breast cancer. Patients and Methods. Patients received pertuzumab/placebo at 840 mg in cycle 1 and 420 mg in subsequent cycles, and trastuzumab at 8 mg/kg in cycle 1 and 6 mg/kg in subsequent cycles; docetaxel was initiated at 75 mg/m2. All study drugs were given intravenously, 3 times weekly. Results. Docetaxel dose reductions below 75 mg/m2 were more common in patients from Asia (47.0%) than other regions (13.4%); docetaxel dose escalations to 100 mg/m2 were less frequent in Asia (2.4%) than other regions (18.7%). Rates of edema (26.1% and 5.4% for Asia and other regions, respectively), myalgia (42.3%, 14.7%), nail disorder (39.9%, 15.1%), febrile neutropenia (18.6%, 7.1%), upper respiratory tract infection (25.7%, 10.2%), decreased appetite (47.0%, 19.1%), and rash (44.3%, 22.0%) were at least twice as high in Asia as in other regions. Adverse events did not result in a reduction in the median number of study treatment cycles administered in patients from Asia. Efficacy analyses per region showed hazard ratios similar to those of the whole intention-to-treat (ITT) population for progression-free survival (ITT: 0.63; Asia: 0.68; other regions: 0.61) and overall survival (ITT: 0.66; Asia: 0.64; other regions: 0.66). Conclusion. Despite a higher proportion of docetaxel dose reductions in patients from Asia, survival benefits were comparable between regions. The benefit-risk profile of pertuzumab, trastuzumab, and docetaxel supports this regimen as the first-line therapy for patients with HER2-positive metastatic breast cancer from all geographic regions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text